AmgenvsRapport Therapeutics

AMGN and RAPP stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$456.70

Value $246B

-1.22%
AMGN's page

RAPP

Rapport Therapeutics, Inc.

$23.78

Value $1.1B

-4.47%
RAPP's page

Amgen (AMGN) has a market value of $246B and Rapport Therapeutics (RAPP) $1.1B. Over the last year, with dividends, AMGN moved +39.4% and RAPP -2.4%. Dividend yield: AMGN 2.18%, RAPP none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$246B

    RAPP$1.1B

    AMGN is 217 times RAPP

  • Revenue, 12 months

    AMGN$38.9B

    RAPP–

  • Net income, 12 months

    AMGN$9.4B

    RAPP-$150M

  • Operating margin

    AMGN32.4%

    RAPP–

  • ROIC

    AMGN16.2%

    RAPP-20.4%

    36.6 points apart

  • P/E

    AMGN26.2

    RAPP–

  • Dividend yield

    AMGN2.2%

    RAPP0.0%

    2.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+39.4%

RAPP-2.4%

100150200DecFebAprJunAugOct
Returns by period
PeriodAMGNWith dividendsRAPPWith dividends
1 year since November 14, 2025+39.4%Price +35.6%-2.4%Price -2.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenRAPPRapport Therapeutics

Valuation

AMGNRAPP
Valuation
Price$456.70$23.78
Market value$246B$1.1B
Enterprise value (EV)$287B$742M
P/E26.2–
P/E, 5-year median23.0–
P/B17.22.9
EV/EBIT22.8–
Free cash flow yield3.9%–

Results and growth

AMGNRAPP
Results and growth
Revenue, 12 months$38.9B–
Net income, 12 months$9.4B-$150M
Free cash flow, 12 months$9.6B-$121M
Earnings per share, 12 months$17.25-$3.16
Revenue growth, year on year10.0%–
Revenue growth a year, past+7.6%over 5 years–
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNRAPP
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%–
Net margin24.1%–
ROIC16.2%-20.4%
ROE87.8%-33.0%

Balance sheet

AMGNRAPP
Balance sheet
Cash$13.2B$395M
Total debt$54.0B$9.4M
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNRAPP
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–0.0%
Shareholder yield2.2%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or RAPP

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Rapport Therapeutics?

By market value, Amgen ($246B) is about 216.6 times Rapport Therapeutics ($1.1B), at today's prices.

How did AMGN and RAPP stock do over the last 1 years?

Since November 14, 2025, AMGN's price moved +35.6% and RAPP's -2.4%. With dividends: AMGN +39.4% (+39.4% a year), RAPP -2.4% (-2.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or RAPP?

The dividend yield at today's price is 2.18% for Amgen and none for Rapport Therapeutics. Over the last twelve months they paid $9.94 and – per share.

Which is the better investment, Amgen or Rapport Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.